BioStock: BiBBInstruments continues to lay groundwork for commercialisation
With the release of the Q3 report, Swedish medtech BibbInstruments continues to make the case that it has what it takes to make an impact on the fast-growing endoscopic ultrasound market. With two ongoing pilot clinical trials on their way towards finalisation with the core biopsy instrument EndoDrill Model X, the cancer diagnostics company has been diligent in preparing the regulatory framework necessary for potential commercialisation in both Europe and the US once clinical evaluation is complete.
Read the article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se